Amgen (NASDAQ:AMGN) Price Target Lowered to $295.00 at Citigroup
Amgen (NASDAQ:AMGN – Free Report) had its price target decreased by Citigroup from $310.00 to $295.00 in a research report released on Tuesday morning,Benzinga reports. Citigroup currently has a neutral rating on the medical research company’s stock.
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Amgen (NASDAQ:AMGN – Get Free Report) is expected to be issuing its quarterly earnings data after the market closes on ...
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
and a greater chance its share price will fall too. Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Thousand Oaks, CA-based Amgen is one of the biggest biotech ...
The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks. Thousand Oaks, CA-based Amgen is one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback